

4.6: Prostate adenocarcinoma

4.7: Renal cell carcinoma

Pr Olivier Detry
Dpt of Abdominal Surgery and Transplantation
CHU Liege, University of Liege
Belgium

Disclosure

I declare that there are no conflicts of interest* in relation to this presentation

*A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk but should be explicitly declared. These may include financial interests (eg. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

4.6: Prostate adenocarcinoma

- Increased incidence with age in male general population & in male organ donors
- - < 50 years: 0.5%
- - 50-59 years: 23%
- - 60-69 years: 35%
- - >70 years: 45%

Yin et al, J Urol 2008

4.6: Prostate adenocarcinoma

- 2 case reports of prostate cancer transmission with organ transplantation
 - 1 LT was diagnosed 2 months after LT
 - 1 case of a heart recipient

Sanchez-Montes C et al, Am J Gastroenterol 2019

Loh E et al, Jama 1997

4.6: Prostate adenocarcinoma

- PSA dosing: no role in PK detection in deceased organ donors
- No role for active screening of potential donors (US, Rectal exam)

4.6: Prostate adenocarcinoma

- PSA dosing: no role in PK detection in deceased organ donors
- No role for active screening of potential donors (US, Rectal exam)
- Donor with past history of prostate K: Gleason' score
- group 1 Gleason score ≤ 6 (3+3)
- group 2 Gleason score 7 (3+4)
- group 3 Gleason score 7 (4+3)
- group 4 Gleason score 8 (4+4, 3+5, 5+3)
- group 5 Gleason score ≥ 9 (4+5, 5+4, 5+5)



4.6: Prostate adenocarcinoma

- PSA dosing: no role in PK detection in deceased organ donors
- No role for active screening of potential donors (US, Rectal exam)
- Donor with past history of prostate K: Gleason' score
- group 1 Gleason score ≤ 6 (3+3)
- group 2 Gleason score 7 (3+4)
- group 3 Gleason score 7 (4+3)
- group 4 Gleason score 8 (4+4, 3+5, 5+3)
- group 5 Gleason score ≥ 9 (4+5, 5+4, 5+5)

4.6: Prostate adenocarcinoma

- PSA dosing: no role in PK detection in deceased organ donors
- No role for active screening of potential donors (US, Rectal exam)
- Donor with past history of prostate K: Gleason' score
- group 1 Gleason score ≤ 6 (3+3)
- group 2 Gleason score 7 (3+4)
- group 3 Gleason score 7 (4+3)
- group 4 Gleason score 8 (4+4, 3+5, 5+3)
- group 5 Gleason score ≥ 9 (4+5, 5+4, 5+5)
- No go for T3 and T4

4.6: Prostate adenocarcinoma



4.6: Prostate adenocarcinoma

- During surgical procurement, any enlarged (pelvic) lymph node should be analysed by frozen section
- No recommendation for post-mortem histologic analysis of prostate

4.7: Renal cell adenocarcinoma

- No published case of RCC transmission with LT
- Cases of RCC transmission with kidney, heart and/or lung Tx
- Detection:
 - donor US and/or CT
 - during surgery (procurement and/or back-table): frozen section
- Donor with past history of RCC: whole body CT

4.7: Renal cell adenocarcinoma

- **2018 Council of Europe guidelines**
 - RCC **< 1 cm** (stage T1a AJCC 8th edn) and nucleolar grade I/II (Fuhrman grade I/II) can be considered **minimal-risk** for transmission;
 - RCC **1-4 cm** (stage T1a AJCC 8th edn) and nucleolar grade I/II (Fuhrman grade I/II) are considered **low-risk**;
 - RCC **4-7 cm** (stage T1b AJCC 8th edn) and nucleolar grade I/II (Fuhrman grade I/II) are considered **intermediate-risk**;
 - RCC **> 7 cm** (stage T2 AJCC 8th edn) and nucleolar grade I/II (Fuhrman grade I/II) or **Fuhrman grade III-IV** (any T) are considered **high-risk**;
 - **T3/T4 or N+ or M+: CI** to procurement & transplantation

4.7: Renal cell adenocarcinoma

- **2018 Council of Europe guidelines**

- RCC < 1 cm (stage T1a AJCC 8th edn) and nucleolar grade I/II (Fuhrman grade I/II) can be considered **minimal-risk** for transmission;
- RCC 1-4 cm (stage T1a AJCC 8th edn) and nucleolar grade I/II (Fuhrman grade I/II) are considered **low-risk**;
- RCC 4-7 cm (stage T1b AJCC 8th edn) and nucleolar grade I/II (Fuhrman grade I/II) are considered **intermediate-risk**;
- RCC > 7 cm (stage T2 AJCC 8th edn) and nucleolar grade I/II (Fuhrman grade I/II) or **Fuhrman grade III-IV** (any T) are considered **high-risk**;
- **T3/T4 or N+ or M+: CI to procurement & transplantation**

THANK YOU !

